胰高血糖素样肽-1受体激动剂防治成人2型糖尿病合并动脉粥样硬化性心血管疾病的中国专家共识

Chinese Expert Consensus on the use of GLP-1RAs in patients with type 2 diabetes mellitus complicated by arteriosclerotic cardiovascular disease

胰高糖素样肽-1受体激动剂(GLP-1RAs)除具有很强的降糖作用外,也具有很强的心血管保护作用。随着心血管结局研究结果的公布,GLP-1RAs也被证实可显著改善2型糖尿病患者合并动脉粥样硬化性心脏病的远期风险。本共识针对GLP-1RAs药理学、心血管保护机制、循证医学证据、临床应用建议、不良反应及注意事项等临床问题给出具体的推荐意见。

Glucagon like peptide-1 receptor agonists(GLP-1RAs)not only have strong hypoglycemic effects,but also have strong cardiovascular protective effects.With the announcement of cardiovascular outcomes,GLP-1RAs have been proved to improve the long-term risk of type 2 diabetes patients with atherosclerotic heart disease significantly.This consensus provides specific recommendations on clinical issues such as GLP-1RAs pharmacology,cardiovascular protection mechanisms,evidence-based medical evidence,clinical application recommendations,adverse reactions,and precautions.